FPT and De Heus Partner to Elevate Security Operations in High-Tech Agribusiness
25.3.2024 11:06:00 EET | Business Wire | Press release
Global IT corporation FPT and De Heus recently entered a strategic partnership to foster the agriculture giant's security operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320729005/en/
De Heus Vietnam COO Rick van der Linden (L) and FPT Software Europe CEO Tran Van Dung (R) at the signing ceremony attended by senior leaders of the Netherlands government during the economic mission to Vietnam (Photo: Business Wire)
The two firms will join forces to support De Heus’ Security Operations Center, focusing on the scope of Security Information and Event Management (SIEM). Leveraging FPT's prowess in technology and high-quality workforce, this movement will bolster De Heus’ capabilities in terms of system monitoring, security breach detection, and defense measures to effectively mitigate cyber risk and safeguard its information system and security data on a global scale.
The partnership marks a significant milestone for De Heus' digital transformation strategy amid rising cyberattack concerns in the manufacturing and agriculture industries. Both parties expect this to set a solid foundation for future collaborations in other areas like artificial intelligence, machine learning, big data, and more to further advance De Heus' and the agriculture industry's growth.
Tran Van Dung, Chief Executive Officer of FPT Software Europe, said: “While all businesses want to scale their digital transformation initiatives quickly, doing so securely is equally imperative in the face of cyber threats. Leveraging our extensive expertise and demonstrated success in deploying SIEM projects for multinational corporations globally, we stand ready to optimize De Heus' security operations.”
Rick van der Linden, Chief Operating Officer of De Heus Viet Nam, shared: “Through this partnership, FPT and De Heus are committing to leveraging our collective expertise and resources to develop robust security frameworks that will withstand the test of time. Together, we will explore innovative solutions and best practices to enhance cybersecurity measures and protect against emerging threats.”
The signing ceremony was attended by the Netherlands Minister of Infrastructure and Water Management, Mark Harbers; Minister of Agriculture, Nature, and Food Quality, Christianne van der Wal; Chair of the Confederation of Netherlands Industry and Employers, Ingrid Thijssen; and over 140 large enterprises from the Netherlands in pivotal fields of high-tech manufacturing, sustainable agriculture and food production, renewable energy, logistics, and climate adaptation and water.
Established its first office in 2008 in France, FPT has expanded its presence to 16 offices across 9 countries, serving over 70 leading businesses across Europe. Over the past decade, the tech firm has also been actively intensifying its local footprint and delivery capabilities through partnerships and acquisitions ventures, notably with the acquisition of RWE IT Slovakia, a subsidiary of European energy giant RWE in 2014, and the French IT Consulting Firm AOSIS in 2023.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 73,000 employees. For more information, please visit https://fpt.com.vn/en.
About De Heus
De Heus Vietnam, a member of Royal De Heus Group, has been proud to be Vietnam's leading animal feed supplier since 2008. De Heus provides farmers comprehensive nutritional solutions to help improve livestock productivity and product quality. With a team of experienced experts and a modern factory system, De Heus is committed to providing high-quality animal feed for all types of animals, from livestock, poultry, and aquaculture to pets. De Heus' reputable brands, such as De Heus, Windmill, Koudijs, Con Cò, and Anco, have become familiar to Vietnamese farmers. De Heus always accompanies Vietnamese farmers, aiming towards developing a sustainable and prosperous agriculture.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320729005/en/
Contact information
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom